Severe Infection

  • Zerbaxa 2017 report

    Zerbaxa 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Avycaz 2016 report

    Avycaz 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Cubicin 2016 report

    Cubicin 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Dalvance 2016 report

    Dalvance 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Invanz 2016 report

    Invanz 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 32 Pages The 5 Key Questions Addressed by this Report:...

  • Sivextro 2016 report

    Sivextro 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Teflaro 2016 report

    Teflaro 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Vibativ 2016 report

    Vibativ 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Zerbaxa 2016 report

    Zerbaxa 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Avycaz 2015 report

    Avycaz 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Cubicin 2015 report

    Cubicin 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Dalvance 2015 report

    Dalvance 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by this...